Monday, December 18, 2006

New Study Shows Efficacy Of AROMASIN On Early Breast Cancer

New data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 study, presented today at the San Antonio Breast Cancer Symposium, showed that postmenopausal women with hormone receptor-positive breast cancer who received Aromasin after five years of tamoxifen were 56% less likely to have a relapse of breast cancer than those who received placebo (P=0.004).“Aromasin provided patients with improved relapse-free survival despite early study closure, unblinding and crossover in the placebo arm,” said Dr. Terry Mamounas, NSABP breast committee chairman and lead investigator for the B-33 study. Median follow-up of 30 months also showed that disease-free survival was improved by 32% (P=0.07). Toxicity experienced with Aromasin in the B-33 trial was acceptable for the adjuvant setting. --Click the title of this post to read the full article from its source--

Labels: , , , , , , ,

/* WebRing Code */